The disability-adjusted life year (DALY) is a generic measure of
health effect that can be used in cost-effectiveness analysis as an
alternative to the quality-adjusted life year (QALY). Infectious
diseases are one of the major to cause significant losses of DALY
and QALY. Human infectious diseases are disorders that are
triggered by the micro-organisms such as bacteria, fungi, viruses,
or parasites. The majority of such diseases are contagious and
create a public health menace. There are several reasons why
infectious diseases are deadly diseases, and one of the primary
reasons is the drug resistance developed over time. Drug
resistance-associated mutations are linked to increasing drug
efflux, modifications of the drugs, or their targets. Every year,
new drugs are being approved by FDA to treat infectious diseases.
Nonetheless, the infectious diseases will undoubtedly persist as
permanent and main threats to humanity for now and in the future,
primarily due to increased longevity that almost always comes at a
cost of impaired immunity. A total of four books are covered under
the series of Infectious drug diseases. - Malarial drug delivery
systems - Tubercular drug delivery systems - Viral drug delivery
systems - Infectious disease drug delivery systems The third volume
of series is focused on viral drug delivery systems. Typically,
virus attaches to the cells (referred as host cell) and releases
its DNA or RNA inside the cell. In second stage, virus’s genetic
material takes control of the cell and forces it to replicate the
virus leading to onset of disease symptoms. DNA class of viruses
include Herpes, Papilloma and Adeno viruses. RNA class of viruses
include retroviruses, such as HIV immunodeficiency virus and SARS
COV – 2 / Corona virus. This book addresses recent developments
in viral drug delivery systems. It covers many different aspects of
viral infections, ways to treat them using modern drug delivery
systems like nano particulate carriers. The choice of viral
delivery systems mainly depends upon the type of virus, duration of
life cycle, presence of drug resistance, cellular and mucosal
interaction of virus, accordingly gene or non-gene drug delivery
systems are selected. Besides that, this book also reports global
dynamics of viral diseases, future predictions of infection rate,
current treatment options, details of drug carriers like
nanoemulsions, polymeric nanoparticles, role of
biofunctionalization, and phyto-molecules in treatment of viral
infections particularly herpes, Covid-19, Ebola, HIV/AIDS,
influenza and viral hepatitis. Audiences from a broad range of
groups, from researchers, academicians, and public health bodies to
regulatory experts, can benefit from the compiled information to
learn more about patient needs and current research advances in the
field of viral drug delivery research.
General
Imprint: |
Springer International Publishing AG
|
Country of origin: |
Switzerland |
Release date: |
April 2023 |
First published: |
2023 |
Editors: |
Ranjita Shegokar
• Yashwant Pathak
|
Dimensions: |
235 x 155mm (L x W) |
Format: |
Hardcover
|
Pages: |
409 |
Edition: |
1st ed. 2023 |
ISBN-13: |
978-3-03-120536-1 |
Categories: |
Books
Promotions
|
LSN: |
3-03-120536-7 |
Barcode: |
9783031205361 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!